Maven Securities LTD Buys Shares of 50,000 Ascendis Pharma A/S (NASDAQ:ASND)

Maven Securities LTD purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 50,000 shares of the biotechnology company’s stock, valued at approximately $7,466,000. Ascendis Pharma A/S makes up about 0.1% of Maven Securities LTD’s investment portfolio, making the stock its 21st largest position. Maven Securities LTD owned 0.08% of Ascendis Pharma A/S at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Loomis Sayles & Co. L P grew its stake in Ascendis Pharma A/S by 35.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company’s stock valued at $27,566,000 after acquiring an additional 48,120 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in Ascendis Pharma A/S by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock valued at $1,664,000 after buying an additional 4,338 shares in the last quarter. Evolutionary Tree Capital Management LLC boosted its holdings in Ascendis Pharma A/S by 82.3% in the 2nd quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company’s stock worth $3,391,000 after buying an additional 11,223 shares during the last quarter. SG Americas Securities LLC increased its stake in Ascendis Pharma A/S by 221.0% during the 2nd quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company’s stock worth $833,000 after buying an additional 4,205 shares in the last quarter. Finally, First Turn Management LLC raised its holdings in shares of Ascendis Pharma A/S by 23.1% during the second quarter. First Turn Management LLC now owns 186,581 shares of the biotechnology company’s stock valued at $25,446,000 after acquiring an additional 34,994 shares during the last quarter.

Ascendis Pharma A/S Stock Down 1.6 %

NASDAQ:ASND opened at $131.35 on Wednesday. Ascendis Pharma A/S has a 52 week low of $101.43 and a 52 week high of $161.00. The stock’s fifty day moving average is $131.37 and its two-hundred day moving average is $132.53. The stock has a market capitalization of $7.97 billion, a price-to-earnings ratio of -16.26 and a beta of 0.67.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. On average, sell-side analysts expect that Ascendis Pharma A/S will post -7.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ASND has been the subject of several research reports. Jefferies Financial Group boosted their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. decreased their price target on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. The Goldman Sachs Group raised their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Wedbush reissued an “outperform” rating and set a $181.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $191.77.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.